Infections caused by multidrug-resistant gram-negative bacteria have emerged as a major threat to public health worldwide. The high mortality and prevalence, along with the slow pace of new antibiotic discovery, highlight the necessity for new disease management paradigms. Here, we report on the development of a multiantigenic nanotoxoid vaccine based on macrophage membrane-coated nanoparticles for eliciting potent immunity against pathogenic Pseudomonas aeruginosa. The design of this biomimetic nanovaccine leverages the specific role of macrophages in clearing pathogens and their natural affinity for various virulence factors secreted by the bacteria. It is demonstrated that the macrophage nanotoxoid is able to display a wide range of P. aeruginosa antigens, and the safety of the formulation is confirmed both in vitro and in vivo. When used to vaccinate mice via different administration routes, the nanotoxoid is capable of eliciting strong humoral immune responses that translate into enhanced protection against live bacterial infection in a pneumonia model. Overall, the work presented here provides new insights into the design of safe, multiantigenic antivirulence vaccines using biomimetic nanotechnology and the application of these nanovaccines towards the prevention of difficult-to-treat gram-negative infections.
immunotherapy is a powerful tactic that can synergistically amplify efficacy by addressing tumor immunosuppression from multiple angles. [7] Overall, combinatorial approaches hold great promise for expanding the utility of immunotherapies across a wider range of patients.Microrobotic platforms, with their ability to actively deliver a diverse range of cargoes, have garnered significant attention over the past decade given their potential to be used for biomedical applications. [8][9][10][11][12][13][14] Compared with traditional delivery systems that rely on passive transport, microrobots utilize various actuation mechanisms to achieve active delivery that can more rapidly or more specifically localize a payload to a desired target. [15][16][17] These systems can also be designed with different biocompatible materials, such as magnesium (Mg) or zinc, to take advantage of the body's natural fluids for propulsion. [18][19][20] Recently, it has been shown that surface functionalization of micromotors can be readily achieved using cell membrane coating technology, [21][22][23] enabling the resulting biomimetic construct to more effectively interface with its surroundings. [24,25] Despite the numerous advantages of microrobots, their use for in vivo applications is still in its infancy. [8,26] Thus far, the majority of studies have focused on the gastrointestinal tract, where microrobots have been used for detoxification, drug delivery, and immune modulation. [27] In order to push the microrobotics field forward and to expand their clinical utility, the identification of novel areas in which these platforms can excel is imperative.Here, we report the development of a microrobot-based strategy that combines tissue disruption and biological stimulation at a tumor site toward enhanced cancer immunotherapy. Specifically, we utilized a Mg-based micromotor system that can interact with aqueous media to generate a reaction within a solid tumor, resulting in the disruption of the surrounding tumor tissue (Figure 1a). The compromised cancer cells could then act as a source of tumor antigens that were phagocytosed by local antigen-presenting cells to train the immune system. [28][29][30] To enhance their immune recruitment capability, the micromotors were loaded with bacteria-derived outer membrane vesicles (OMVs), [31] which contain a range of immunostimulatory molecules that have been leveraged for cancer treatment. [32][33][34] When administered intratumorally, the OMV-loadedThe combination of immunotherapy with other forms of treatment is an emerging strategy for boosting antitumor responses. By combining multiple modes of action, these combinatorial therapies can improve clinical outcomes through unique synergisms. Here, a microrobot-based strategy that integrates tumor tissue disruption with biological stimulation is shown for cancer immunotherapy. The microrobot is fabricated by loading bacterial outer membrane vesicles onto a self-propelling micromotor, which can react with water to generate a propulsion force. When adm...
Cancer vaccines are promising treatments to prevent relapse after chemotherapy in acute myeloid leukemia (AML) patients, particularly for those who cannot tolerate intensive consolidation therapies. Here, we report the development of an AML cell membrane-coated nanoparticle (AMCNP) vaccine platform, in which immune-stimulatory adjuvant-loaded nanoparticles are coated with leukemic cell membrane material. This AMCNP vaccination strategy stimulates leukemia-specific immune responses by co-delivering membrane-associated antigens along with adjuvants to antigen-presenting cells. To demonstrate that this AMCNP vaccine enhances leukemia-specific antigen presentation and T cell responses, we modified a murine AML cell line to express membrane-bound chicken ovalbumin as a model antigen. AMCNPs were efficiently acquired by antigen-presenting cells in vitro and in vivo and stimulated antigen cross-presentation. Vaccination with AMCNPs significantly enhanced antigen-specific T cell expansion and effector function compared with control vaccines. Prophylactic vaccination with AMCNPs enhanced cellular immunity and protected against AML challenge. Moreover, in an AML post-remission vaccination model, AMCNP vaccination significantly enhanced survival in comparison to vaccination with whole leukemia cell lysates. Collectively, AMCNPs retained AML-specific antigens, elicited enhanced antigen-specific immune responses, and provided therapeutic benefit against AML challenge.
There is an unmet need for novel and efficacious therapeutics for regenerating injured articular cartilage in progressive osteoarthritis (OA) and/or trauma. Mesenchymal stem cells (MSCs) are particularly promising for their chondrogenic differentiation, local healing environment modulation, and tissue- and organism-specific activity; however, despite early in vivo success, MSCs require further investigation in highly-translatable models prior to disseminated clinical usage. Large animal models, such as canine, porcine, ruminant, and equine models, are particularly valuable for studying allogenic and xenogenic human MSCs in a human-like osteochondral microenvironment, and thus play a critical role in identifying promising approaches for subsequent clinical investigation. In this mini-review, we focus on [1] considerations for MSC-harnessing studies in each large animal model, [2] source tissues and organisms of MSCs for large animal studies, and [3] tissue engineering strategies for optimizing MSC-based cartilage regeneration in large animal models, with a focus on research published within the last 5 years. We also highlight the dearth of standard assessments and protocols regarding several crucial aspects of MSC-harnessing cartilage regeneration in large animal models, and call for further research to maximize the translatability of future MSC findings.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.